Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.34 USD | -1.76% | -5.68% | -8.68% |
Mar. 12 | Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says | MT |
Mar. 11 | Transcript : Incyte Corporation - Shareholder/Analyst Call |
Financials (USD)
Sales 2024 * | 4.14B | Sales 2025 * | 4.61B | Capitalization | 12.87B |
---|---|---|---|---|---|
Net income 2024 * | 838M | Net income 2025 * | 1.04B | EV / Sales 2024 * | 2.03 x |
Net cash position 2024 * | 4.47B | Net cash position 2025 * | 5.78B | EV / Sales 2025 * | 1.54 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
12.7
x | Employees | 2,524 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.3% |
Latest transcript on Incyte Corporation
1 day | -1.76% | ||
1 week | -5.68% | ||
Current month | -1.75% | ||
1 month | -1.07% | ||
3 months | -5.41% | ||
6 months | -3.65% | ||
Current year | -8.68% |
Managers | Title | Age | Since |
---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
Director of Finance/CFO | 53 | 19-02-10 | |
Pablo Cagnoni
PSD | President | 60 | 23-06-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
Director/Board Member | 70 | 15-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.55% | 227 M€ | +9.20% | - | |
2.94% | 1 M€ | -.--% | - | |
2.88% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 57.34 | -1.76% | 1,811,547 |
24-03-15 | 58.37 | -0.29% | 4,901,969 |
24-03-14 | 58.54 | -0.64% | 1,230,862 |
24-03-13 | 58.92 | -0.69% | 1,335,486 |
24-03-12 | 59.33 | -2.40% | 1,643,796 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.68% | 12.87B | |
-2.61% | 88.56B | |
+13.03% | 45.79B | |
+36.25% | 22.19B | |
-17.46% | 16.82B | |
-13.08% | 15.81B | |
-2.24% | 12.94B | |
+0.30% | 8.71B | |
-9.01% | 8.78B | |
+105.08% | 8.02B |